Sustained release and pharmacologic evaluation of human glucagon-like peptide-1 and liraglutide from polymeric microparticles

References

• Abbott, C.R., et al., 2005. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain research, 1044(1), 127–131.
   PubMed Web of Science ®Google Scholar
• Agersø, H. and Vicini, P., 2003. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. European journal of pharmaceutical sciences, 19(2–3), 141–150.
   PubMed Web of Science ®Google Scholar
• Ahrén, B. and Schmitz, O., 2004. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Hormone and metabolic research, 36(11/12), 867–876.
   PubMed Web of Science ®Google Scholar
• Allahyari, M. and Mohit, E., 2015. Peptide/protein vaccine delivery system based on PLGA particles. Human vaccines & immunotherapeutics, 12(3), 806–828.
   Web of Science ®Google Scholar
• Aroda, V.R. and DeYoung, M.B., 2011. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes. Postgraduate medicine, 123(5), 228–238.
   PubMed Web of Science ®Google Scholar
• Bethel, M.A., et al., 2018. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. The lancet diabetes & endocrinology, 6(2), 105–113.
   PubMed Web of Science ®Google Scholar
• Bodmer, D., Kissel, T., and Traechslin, E., 1992. Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems. Journal of controlled release, 21(1–3), 129–137.
   Web of Science ®Google Scholar
• Brunton, S., 2014. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? International journal of clinical practice, 68(5), 557–567.
   PubMed Web of Science ®Google Scholar
• Cai, Y., et al., 2013. Long-acting preparations of exenatide. Drug Design, Development and therapy, 7, 963–970.
   PubMed Web of Science ®Google Scholar
• Das, S.K., et al., 2015. Formulation development and statistical optimization of ibuprofen-loaded polymethacrylate microspheres using response surface methodology. Chemical engineering research and design, 96, 1–14.
   Web of Science ®Google Scholar
• DeFronzo, R.A., et al., 2005. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes care, 28(5), 1092–1100.
   PubMed Web of Science ®Google Scholar
• El-Say, K.M., 2016. Maximizing the encapsulation efficiency and the bioavailability of controlled-release cetirizine microspheres using Draper–Lin small composite design. Drug Design. Development and therapy, 10, 825–839.
   PubMed Web of Science ®Google Scholar
• Emulsion Solvent Evaporation Microencapsulation Review | Emulsion | Polyethylene Glycol [online], 2017. Scribd. Available from: https://es.scribd.com/document/284394619/Emulsion-Solvent-Evaporation-Microencapsulation-Review [Accessed 23 Jun 2017].
   Google Scholar
• Essa, S., Rabanel, J.M., and Hildgen, P., 2010. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly(d, l-lactide) (PLA) based nanoparticles. European journal of pharmaceutics and biopharmaceutics, 75(2), 96–106.
   PubMed Web of Science ®Google Scholar
• FDA Approves Liraglutide (Saxenda) for Weight Loss [online], 2017. Medscape. Available from: http://www.medscape.com/viewarticle/837147 [Accessed 24 Oct 2017].
   Google Scholar
• Frias, J.P., 2019. Prioritising injectable therapies in the management of type 2 diabetes. The lancet diabetes & endocrinology, 7(7), 505–508.
   PubMed Web of Science ®Google Scholar
• Gough, S.C.L., 2012. Liraglutide: from clinical trials to clinical practice. Diabetes, obesity and metabolism, 14(Suppl 2), 33–40.
   PubMed Web of Science ®Google Scholar
• Guerreiro, L.H., et al., 2012. A fluorescence-based assay for octreotide in kinetic release from depot formulations. Química nova, 35(5), 1025–1029.
   Web of Science ®Google Scholar
• Han, F.Y., et al., 2016. Bioerodable PLGA-based microparticles for producing sustained-release drug formulations and strategies for improving drug loading. Frontiers in pharmacology, 7, 185.
   PubMed Web of Science ®Google Scholar
• Holst, J.J., 2007. The physiology of glucagon-like peptide 1. Physiological reviews, 87(4), 1409–1439.
   PubMed Web of Science ®Google Scholar
• Icart, L.P., et al., 2016. Fluorescent microspheres of poly(ethylene glycol)-poly(lactic acid)-fluorescein copolymers synthesized by Ugi four-component condensation. Journal of applied polymer science, 133(9), 42994.
   Web of Science ®Google Scholar
• Isaacs, D., Prasad-Reddy, L., and Srivastava, S.B., 2016. Role of glucagon-like peptide 1 receptor agonists in management of obesity. American journal of health-system pharmacy, 73(19), 1493–1507.
   PubMed Web of Science ®Google Scholar
• Kadam, N.R., and Suvarna, V., 2015. Microsphere: a brief review. Asian journal of biomedical and pharmaceutical sciences, 5(47), 13–19.
   Google Scholar
• Kamaly, N., et al., 2016. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chemical reviews, 116(4), 2602–2663.
   PubMed Web of Science ®Google Scholar
• Kim, H.J., and Kim, D.J., 2017. Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes. Journal of diabetes investigation, 8(4), 431–433.
   PubMed Web of Science ®Google Scholar
• Larsen, P.J., et al., 2001. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes, 50(11), 2530–2539.
   PubMed Web of Science ®Google Scholar
• Lim, S., Kim, K.M., and Nauck, M.A., 2018. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends in endocrinology & metabolism, 29(4), 238–248.
   PubMed Web of Science ®Google Scholar
• Liu, B., et al., 2010. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres. Chemical & pharmaceutical bulletin, 58(11), 1474–1479.
   PubMed Web of Science ®Google Scholar
• Lochmann, A., et al., 2010. The influence of covalently linked and free polyethylene glycol on the structural and release properties of rhBMP-2 loaded microspheres. Journal of controlled release, 147(1), 92–100.
   PubMed Web of Science ®Google Scholar
• Madsbad, S., 2009. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results. Best practice & research clinical endocrinology & metabolism, 23(4), 463–477.
   PubMed Web of Science ®Google Scholar
• Madsbad, S., et al., 2004. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (nn2211) a 12-week, double-blind, randomized, controlled trial. Diabetes care, 27(6), 1335–1342.
   PubMed Web of Science ®Google Scholar
• Makadia, H.K., and Siegel, S.J., 2011. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377–1397.
   PubMed Web of Science ®Google Scholar
• Marso, S.P., et al., 2016. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England journal of medicine, 375(4), 311–322.
   PubMed Web of Science ®Google Scholar
• Minze, M.G., et al., 2013. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus. Pharmacotherapy: the journal of human pharmacology and drug therapy, 33(6), 627–638.
   Google Scholar
• Parikh, R.H., et al., 2003. Poly(D,L-lactide-co-glycolide) microspheres containing 5-fluorouracil: optimization of process parameters. AAPS pharmscitech, 4(2), 14–21.
   Google Scholar
• Pinelli, N.R., and Hurren, K.M., 2011. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Annals of pharmacotherapy, 45(7-8), 850–860.
   PubMed Web of Science ®Google Scholar
• Ponzani, P., 2013. Long-term effectiveness and safety of liraglutide in clinical practice. Minerva endocrinologica, 38(1), 103–112.
   PubMed Web of Science ®Google Scholar
• Ravi, S., et al., 2008. Development and characterization of polymeric microspheres for controlled release protein loaded drug delivery system. Indian journal of pharmaceutical sciences, 70(3), 303.
   PubMed Web of Science ®Google Scholar
• Ronveaux, C.C., Tomé, D., and Raybould, H.E., 2015. Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling12. The journal of nutrition, 145(4), 672–680.
   PubMed Web of Science ®Google Scholar
• Ruan, G., and Feng, S.-S., 2003. Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials, 24(27), 5037–5044.
   PubMed Web of Science ®Google Scholar
• Rüttimann, E.B., et al., 2009. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology, 150(3), 1174–1181.
   PubMed Web of Science ®Google Scholar
• Ryan, G.J., Moniri, N.H., and Smiley, D.D., 2013. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. American journal of health-system pharmacy, 70(13), 1123–1131.
   PubMed Web of Science ®Google Scholar
• Sjöholm, Å., 2010. Liraglutide therapy for type 2 diabetes: overcoming unmet needs. Pharmaceuticals, 3(3), 764–781.
   Google Scholar
• Song, Y.-P., et al., 2011. A method for simultaneously improving the flame retardancy and toughness of PLA. Polymers for advanced technologies, 22(12), 2295–2301.
   Web of Science ®Google Scholar
• Talsania, T., et al., 2005. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology, 146(9), 3748–3756.
   PubMed Web of Science ®Google Scholar
• Tang-Christensen, M., et al., 1996. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. The American journal of physiology, 271(4 Pt 2), R848–856.
   PubMed Web of Science ®Google Scholar
• Tu, F., and Lee, D., 2012. Controlling the stability and size of double-emulsion-templated poly(lactic-co-glycolic) acid microcapsules. Langmuir, 28(26), 9944–9952.
   PubMed Web of Science ®Google Scholar
• Turton, M.D., et al., 1996. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature, 379(6560), 69–72.
   PubMed Web of Science ®Google Scholar
• Udenfriend, S., et al., 1972. Fluorescamine: a reagent for assay of amino acids, peptides, proteins, and primary amines in the picomole range. Science (science.), 178(4063), 871–872.
   PubMed Web of Science ®Google Scholar
• Williams, D.L., Baskin, D.G., and Schwartz, M.W., 2009. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology, 150(4), 1680–1687.
   PubMed Web of Science ®Google Scholar
• Wismann, P., et al., 2018. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice. Physiology & behavior, 192, 72–81.
   PubMed Web of Science ®Google Scholar
• Wu, J., et al., 2016. Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: Preparation and in vivo evaluation. European journal of pharmaceutical sciences, 92, 28–38.
   PubMed Web of Science ®Google Scholar
• Xu, X.-J., Ye, Y.-H., and Tam, J. P., 2006. Peptides: Biology and chemistry. Springer Science & Business Media.
   Google Scholar
• Yang, Q., and Owusu-Ababio, G., 2000. Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug development and industrial pharmacy, 26(1), 61–70.
   PubMed Web of Science ®Google Scholar
• Yin, D., et al., 2006. [Long-acting injectable microspheres of glucagon-like peptide-1]. Yao xue xue bao = acta pharmaceutica sinica, 41(7), 603–607.
   PubMedGoogle Scholar
• Yin, D.-F., et al., 2005. Studies on the preparation and release in vitro of the glucagon-like peptide - 1 loaded long-acting injectable microspheres. Pharmaceutical care and research, 5(3), 243–247.
   Google Scholar
• Yüksel, N., and Baykara, T., 1997. Preparation of polymeric microspheres by the solvent evaporation method using sucrose stearate as a droplet stabilizer. Journal of microencapsulation, 14(6), 725–733.
   PubMed Web of Science ®Google Scholar
• Zander, M., et al., 2002. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet (London, England), 359(9309), 824–830.
   PubMed Web of Science ®Google Scholar